Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the HARMONY 360 investigation is to explore the feasibility of using MyoSense 360 digital measures to develop models capable of detecting clinically meaningful changes in generalized Myasthenia Gravis (gMG) trajectory over 12 months under real-world conditions. Its main objective is not yet to demonstrate the final conformity of the device (exploratory study under article 82), but to collect preliminary data of safety and clinical performance that will help to refine the final product and inform the subsequent pivotal study.
The primary objective focuses on developing models to detect disease trajectory changes defined by the clinically significant +/- 2 points MG-ADL threshold. Secondary objectives include assessing usability, adherence, and the feasibility of models for worsening/exacerbation prediction. Finally, risks and anticipated Adverse Device Effects (ADEs) associated with the device use will be monitored continuously throughout the investigation. Consistent with its Proof of Concept stage, the study defines no claims of clinical performance, effectiveness or safety.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MyoSense 360 | Experimental | Performance of digital tests (only at D0), digital questionnaires and standard test in clinic at D0, D180 and D360 Use of MyoSense 360 at-home in between visits during 12 months of follow-up and answer ePRO |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MyoSense 360 | Device | The investigational version of MyoSense 360 consists of two mobile applications running on the patient's smartphone (CentrePoint Connect and InClinical), an ActiGraph LEAP activity monitor (Ametris product), as well as two cloud computing platforms |
| Measure | Description | Time Frame |
|---|---|---|
| To explore the feasibility of using digital measures collected by MyoSense 360 to develop models to detect changes in disease trajectory in adults with generalized Myasthenia Gravis over a 12-month period, under real-life, unsupervised conditions. | The primary endpoint will be the ability of the model to detect changes categorized as a 3-class variable:
| 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| To explore the feasibility of using digital measures collected by MyoSense 360 to develop models to predict sustained worsening within a one-month forward-looking window | The first secondary endpoint will be the ability of the model to detect changes categorized as a 2-class variable:
|
Not provided
Inclusion Criteria:
Age ≥ 18 years at screening
Patients with gMG diagnosis confirmed by the investigator based at least on one of the following:
Positive antibody testing for ACHR or MuSK antibodies; or,
MGFA Class IIa to IVb
Having read the information sheet and signed the informed consent form
Owning and able to use a personal smartphone which software version is above 16 for iOS and 8 for Android included
Able to read languages in which the mobile application is available and able to understand pictograms (MyoSense 360 is available in local official languages)
Able to use an activity monitor (per Actigraph LEAP activity monitor wearability criteria; see vendor guidance)
For France only, affiliated with or benefiting from a social security system
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009157 | Myasthenia Gravis |
| ID | Term |
|---|---|
| D020361 | Paraneoplastic Syndromes, Nervous System |
| D009423 | Nervous System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 1 month |
| To describe the association between MyoSense 360 active functional tests combined measures in a model, obtained at home, without supervision and the standard reference QMG sub-items scores performed under clinical supervision at baseline. | Feasibility of using MyoSense 360 developed models to predict sustained worsening, i.e., an increase by at least 2-points in MG-ADL total score that is sustained within the next 4 weeks (no change observed in the opposite direction) will be described through performance metrics: - Positive predictive value | 4 weeks |
| To describe the association between MyoSense 360 active functional tests combined measures in a model, obtained at home, without supervision and the standard reference QMG sub-items scores performed under clinical supervision at baseline. | Feasibility of using MyoSense 360 developed models to predict sustained worsening, i.e., an increase by at least 2-points in MG-ADL total score that is sustained within the next 4 weeks (no change observed in the opposite direction) will be described through performance metrics: - time-to-event accuracy | 4 weeks |
| To describe the association between MyoSense 360 active functional tests combined measures in a model, obtained at home, without supervision and the standard reference QMG sub-items scores performed under clinical supervision at baseline. | Feasibility of using MyoSense 360 developed models to predict sustained worsening, i.e., an increase by at least 2-points in MG-ADL total score that is sustained within the next 4 weeks (no change observed in the opposite direction) will be described through performance metrics: - Model robustness across patients. | 4 weeks |
| To describe the association between MyoSense 360 active functional tests measures obtained at home without supervision and the standard reference Quantitative Myasthenia Gravis (QMG) sub-items performed under clinical supervision at baseline | A correlation coefficient will be used to assess the relationship between the MyoSense 360 active functional tests at Day 1 (D1, at home) and standard tests at Day 0 (D0, in clinic). The endpoint will be considered positive if one test meets the expected correlation, with a minimum correlation threshold of r = 0.50 for the following comparisons:
| Day 0 and Day 1 |
| To describe the association between digital measures from MyoSense 360 (ActiGraph LEAP data collection, active smartphone functional tests and electronic Patient-Reported Outcomes) and clinical and patient-reported outcome measures | Cross-sectional and longitudinal associations between MyoSense 360 digital measures and clinical and patient-reported outcomes measured through questionnaires will be described using mixed-models | 12 months |
| To describe participant compliance to the use of the MyoSense 360, including ActiGraph LEAP data collection all along the study, number of active functional tests performed and ePROs completed | Compliance to MyoSense 360 will be described through: - The number of days with valid* data collection from the wearable device. *The minimum requirement is 8 hours of daytime wear per day, with at least 60% daily compliance throughout the one-year follow-up period. Additionally, patients should wear the ActiGraph LEAP during at least two nights per week to capture relevant sleep and resting heart rate measures. | 12 months |
| To describe the usability of MyoSense 360, including ActiGraph LEAP data collection, active functional tests and ePROs, from the patient's perspective. | Usability of MyoSense 360 will be described using the System Usability Scale (SUS): - A descriptive analysis of the responses collected in the SUS related to the use of MyoSense 360 at Days 1, 180 and 345 | Days 1, 180 and 345 |
| To describe participant compliance to the use of the MyoSense 360, including ActiGraph LEAP data collection all along the study, number of active functional tests performed and ePROs completed | Compliance to MyoSense 360 will be described through: - The proportion of scheduled active functional tests completed per patient over time in comparison to the total expected | 12 months |
| To describe overall patient satisfaction and perceived benefits of using MyoSense 360 in daily life | Descriptive analysis of the answers collected in the patient's satisfaction and perceived benefits questionnaires related to the use of MyoSense 360 | Days 1, 180 and 345 |
| To monitor the incidence, type, and severity of adverse events and device deficiencies related to the use of MyoSense 360. | All adverse events (AEs), serious adverse events (SAEs) and Device Deficiencies (DD), and new findings on previous SAEs and DDs, suspected to be related to MyoSense 360 or not, will be prospectively collected from the first device use until 30 days after the last study activity, in line with ISO 14155:2020 and EU MDR 2017/745. | 390 days |
| D010257 | Paraneoplastic Syndromes |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D019636 | Neurodegenerative Diseases |
| D020511 | Neuromuscular Junction Diseases |
| D009468 | Neuromuscular Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |